SGLT-2 抑制劑於慢性腎臟病之臨床應用與保護機轉

Abstract List

20 Sep 2026 14:00 14:30
Chung-Kuan Wu Speaker SGLT-2 抑制劑於慢性腎臟病之臨床應用與保護機轉 The role of SGLT2 inhibitors in the treatment of diabetic and non-diabetic kidney disease Diabetic kidney disease is a major cause of chronic kidney disease and end-stage kidney disease. In addition to hyperglycemia and metabolic abnormalities, its pathophysiology involves glomerular hyperfiltration, increased intraglomerular pressure, excessive tubular workload, and renal inflammation. Sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) reduce glucose and sodium reabsorption in the proximal tubule, restore tubuloglomerular feedback, lower intraglomerular pressure, decrease tubular workload, and may attenuate renal inflammation. These mechanisms contribute to cardiovascular and kidney protection beyond their glucose-lowering effects. In addition, the sustained beneficial effects extend to non-diabetic kidney disease. Large clinical trials and meta-analyses have demonstrated that SGLT2 inhibitors reduce albuminuria, slow kidney function decline, and decrease cardiovascular and renal adverse events. These benefits were observed in addition to standard treatment with renin–angiotensin system inhibitors. Key topics of the presentation include: 1. The physiological roles of SGLT1 and SGLT2 in the intestine and proximal renal tubule 2. The mechanisms by which SGLT2 inhibition reduces intraglomerular pressure, tubular workload, and renal inflammation 3. Cardiovascular and renal outcomes from the clinical trial, and relevant meta-analyses 4. The role of SGLT2 inhibitors in the comprehensive management of patients with type 2 diabetes and chronic kidney disease according to the KDIGO guideline Overall, SGLT2 inhibitors have evolved from glucose-lowering agents into a fundamental component of cardiovascular and kidney risk management in diabetic kidney disease. Their timely use, based on kidney function, albuminuria, cardiovascular risk, and the overall comorbidity profile, may help delay kidney disease progression and improve long-term clinical outcomes. The role of SGLT2 inhibitors in the treatment of diabetic and non-diabetic kidney disease Diabetic kidney disease is a major cause of chronic kidney disease and end-stage kidney disease. In addition to hyperglycemia and metabolic abnormalities, its pathophysiology involves glomerular hyperfiltration, increased intraglomerular pressure, excessive tubular workload, and renal inflammation. Sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) reduce glucose and sodium reabsorption in the proximal tubule, restore tubuloglomerular feedback, lower intraglomerular pressure, decrease tubular workload, and may attenuate renal inflammation. These mechanisms contribute to cardiovascular and kidney protection beyond their glucose-lowering effects. In addition, the sustained beneficial effects extend to non-diabetic kidney disease. Large clinical trials and meta-analyses have demonstrated that SGLT2 inhibitors reduce albuminuria, slow kidney function decline, and decrease cardiovascular and renal adverse events. These benefits were observed in addition to standard treatment with renin–angiotensin system inhibitors. Key topics of the presentation include: 1. The physiological roles of SGLT1 and SGLT2 in the intestine and proximal renal tubule 2. The mechanisms by which SGLT2 inhibition reduces intraglomerular pressure, tubular workload, and renal inflammation 3. Cardiovascular and renal outcomes from the clinical trial, and relevant meta-analyses 4. The role of SGLT2 inhibitors in the comprehensive management of patients with type 2 diabetes and chronic kidney disease according to the KDIGO guideline Overall, SGLT2 inhibitors have evolved from glucose-lowering agents into a fundamental component of cardiovascular and kidney risk management in diabetic kidney disease. Their timely use, based on kidney function, albuminuria, cardiovascular risk, and the overall comorbidity profile, may help delay kidney disease progression and improve long-term clinical outcomes.